# Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

> **NCT05596890** · PHASE2 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Patient-reported Outcomes
- Immunotherapy

## Interventions

- **DRUG:** Paclitaxel-albumin
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Tislelizumab
- **RADIATION:** VMAT or IMRT
- **PROCEDURE:** Esophagectomy

## Key facts

- **NCT ID:** NCT05596890
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-30
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05596890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05596890, "Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05596890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*